Bank of New York Mellon’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-408,416
Closed -$7.33M 4487
2017
Q4
$7.33M Sell
408,416
-5,888
-1% -$72.5K ﹤0.01% 2155
2017
Q3
$4.89M Buy
414,304
+47,639
+13% +$534K ﹤0.01% 2349
2017
Q2
$3.85M Sell
366,665
-1,026
-0.3% -$10.5K ﹤0.01% 2455
2017
Q1
$4.04M Buy
367,691
+190,292
+107% +$2.21M ﹤0.01% 2430
2016
Q4
$2.4M Buy
177,399
+46,565
+36% +$650K ﹤0.01% 2742
2016
Q3
$1.61M Buy
130,834
+6,368
+5% +$75K ﹤0.01% 2897
2016
Q2
$1.36M Sell
124,466
-21,335
-15% -$239K ﹤0.01% 2944
2016
Q1
$1.59M Sell
145,801
-228,321
-61% -$2.89M ﹤0.01% 2790
2015
Q4
$6.47M Buy
374,122
+49,119
+15% +$881K ﹤0.01% 2076
2015
Q3
$6.46M Sell
325,003
-14,151
-4% -$324K ﹤0.01% 2091
2015
Q2
$5.57M Sell
339,154
-4,956
-1% -$85.9K ﹤0.01% 2285
2015
Q1
$5.35M Buy
344,110
+254,662
+285% +$3.95M ﹤0.01% 2285
2014
Q4
$1.28M Sell
89,448
-13,998
-14% -$148K ﹤0.01% 3151
2014
Q3
$672K Buy
103,446
+1,137
+1% +$7.55K ﹤0.01% 3512
2014
Q2
$706K Buy
102,309
+888
+0.9% +$6.28K ﹤0.01% 3498
2014
Q1
$725K Buy
101,421
+7,693
+8% +$65.8K ﹤0.01% 3434
2013
Q4
$881K Buy
93,728
+28,090
+43% +$200K ﹤0.01% 3363
2013
Q3
$410K Sell
65,638
-22,928
-26% -$143K ﹤0.01% 3586
2013
Q2
$583K Buy
+88,566
New +$703K ﹤0.01% 3437

Other funds holding SCMP

Bank of New York Mellon's SCMP Position: Q1 2018 in Review

Bank of New York Mellon sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 408,416 shares — an estimated $7.33M sold.

Bank of New York Mellon first reported a position in SCMP in Q2 2013 and held it in 19 quarters. The position peaked at $7.33M in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Bank of New York Mellon reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Bank of New York Mellon sold 408,416 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $7.33M.
  • Bank of New York Mellon first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 19 quarters.
  • Bank of New York Mellon's Sucampo Pharmaceuticals, Inc. position peaked at $7.33M in Q4 2017.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Bank of New York Mellon's 13F filing for Q1 2018, filed 15 May 2018.